Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue

The development of a macromolecular conjugate of a multitargeted tyrosine kinase inhibitor is described that can be used for renal‐specific delivery into proximal tubular cells. A novel sunitinib analogue, that is, 17864, is conjugated to a NH₂‐PAMAM‐G3 dendrimer via the platinum (II)‐based Universal Linkage System (ULS?). The activity of 17864 is retained after coordination to the ULS linker alone or when coupled to NH₂‐PAMAM‐G3. 17864‐UlS‐NH₂‐PAMAM‐G3 is non‐toxic to proximal tubular cells in vitro. After intravenous administration to mice, 17864‐UlS‐NH₂‐PAMAM‐G3 rapidly and efficiently accumulates in the kidneys. These results are encouraging for future studies focusing on the development of novel therapeutics for the treatment of renal diseases.

     

UO22+对某些细胞毒性的初探

建立了由多种金属离子和小分子配体组成的多相细胞液热力学平衡模型,模拟研究了UO22+在组织液和细胞液的形态。体外培养了SD大鼠成骨细胞和人肾小管上皮细胞,通过体外细胞生长抑制实验探索了UO22+对成骨细胞及肾小管上皮细胞的毒性。研究表明,在细胞液中,当各形态UO22+物质总浓度[U]=8.4×10-6mol/L时,当pH为6.0～6.5时,UO22+主要以固相(UO2)3(PO4)2存在,当pH为6.8～7.5时,UO22+主要以水溶性[UO2(CO3)3]4-存在;当[U]=1.3×10-3mol/L时,在整个细胞液pH范围内,固相(UO2)3(PO4)2占主导地位。体外细胞生长抑制实验表明,UO22+对成骨细胞的生长具有抑制作用,能显著降低肾小管上皮细胞的存活率,具有明显的细胞毒性。     

血液净化高分子吸附材料

简要总结了我们近年来在血液净化高分子吸附材料方面取得的研究成果. 对于有机小分子吸附剂、中分子吸附剂和生物大分子吸附剂的系统研究,不仅取得了大量的基础性研究结果,而且筛选出了性能优良的血液净化吸附剂,已经与血液灌流装置一起开始应用于临床.     

鲤鱼组织ATPase活性抑制和构效分析

在离体实验条件下测定了20种硝基芳烃化合物对鲤鱼鳃和肾的ATPase活性的半抑制浓度c_I50值.以辛醇-水分配系数1gp、一阶价分子连接性指数¹x^v、指示变量I、分子分支指数¹K_a、取代基常数总和∑_σ-和分子最低空轨道能E_lumo为参数,依据20种硝基芳烃化合物对鲤鱼鳃和肾的ATPase活性的半抑制浓度-lgc_I50值,进行构效分析,建立了20种硝基芳烃化合物的QSAR方程.结果表明,∑_σ-、I、E_lumo3个参数与硝基芳烃对鲤鱼组织ATPase毒性密切相关,并预测和探讨了毒性作用机制.     

Protective Effects of 6-Shogaol,an Active Compound of Ginger,in a Murine Model of Cisplatin-Induced Acute Kidney Injury

Acute kidney injury (AKI) is a dose-limiting side effect of cisplatin therapy in cancer patients. However, effective therapies for cisplatin-induced AKI are not available. Oxidative stress, tubular cell death, and inflammation are known to be the major pathological processes of the disease. 6-Shogaol is a major component of ginger and exhibits anti-oxidative and anti-inflammatory effects. Accumulating evidence suggest that 6-shogaol may serve as a potential therapeutic agent for various inflammatory diseases. However, whether 6-shogaol exerts a protective effect on cisplatin-induced renal side effect has not yet been determined. The aim of this study was to evaluate the effect of 6-shogaol on cisplatin-induced AKI and to investigate its underlying mechanisms. An administration of 6-shogaol after cisplatin treatment ameliorated renal dysfunction and tubular injury, as shown by a reduction in serum levels of creatinine and blood urea nitrogen and an improvement in histological abnormalities. Mechanistically, 6-shogaol attenuated cisplatin-induced oxidative stress and modulated the renal expression of prooxidant and antioxidant enzymes. Apoptosis and necroptosis induced by cisplatin were also suppressed by 6-shogaol. Moreover, 6-shogaol inhibited cisplatin-induced cytokine production and immune cell infiltration. These results suggest that 6-shogaol exhibits therapeutic effects against cisplatin-induced AKI via the suppression of oxidative stress, tubular cell death, and inflammation.     

Enriching the Arsenal of Pharmacological Tools against MICAL2

Molecule interacting with CasL 2 (MICAL2), a cytoskeleton dynamics regulator, are strongly expressed in several human cancer types, especially at the invasive front, in metastasizing cancer cells and in the neo-angiogenic vasculature. Although a plethora of data exist and stress a growing relevance of MICAL2 to human cancer, it is worth noting that only one small-molecule inhibitor, named CCG-1423 (1), is known to date. Herein, with the aim to develop novel MICAL2 inhibitors, starting from CCG-1423 (1), a small library of new compounds was synthetized and biologically evaluated on human dermal microvascular endothelial cells (HMEC-1) and on renal cell adenocarcinoma (786-O) cells. Among the novel compounds, 10 and 7 gave interesting results in terms of reduction in cell proliferation and/or motility, whereas no effects were observed in MICAL2-knocked down cells. Aside from the interesting biological activities, this work provides the first structure–activity relationships (SARs) of CCG-1423 (1), thus providing precious information for the discovery of new MICAL2 inhibitors.     

Lipidomics based on liquid chromatography-high resolution mass spectrometry reveals the protective role of peroxisome proliferator-activated receptor alpha on kidney stone formation in mice treated with glyoxylate

Few studies have examined the relationship between lipid metabolism and kidney stone formation, particularly the role of key lipid regulatory factors in kidney stone formation. We evaluated the effect of the lipid regulatory factor-peroxisome proliferator-activated receptor alpha on the formation of renal stones in mice by injecting them with glyoxylate followed by treatment with either a peroxisome proliferator-activated receptor alpha agonist fenofibrate or an antagonist GW6471 (GW). Liquid chromatography coupled with trapped ion mobility spectrometry-quadrupole-time-of-flight mass spectrometry-based lipidomics was used to determine the lipid profile in the mouse kidneys. Histological and biochemical analyses showed that the mice injected with glyoxylate exhibited crystal precipitation and renal dysfunction. Crystallization decreased significantly in the fenofibrate group, whereas it increased significantly in the GW group. A total of 184 lipids, including fatty acyls, glycerolipids, glycerophospholipids, and sphingolipids differed significantly between the mice in the model and control groups. Peroxisome proliferator-activated receptor alpha activity negatively correlated with glyoxylate-induced kidney stone formation in mice, which may be related to improved fatty acid oxidation, maintenance of ceramide/complex sphingolipids cycle balance, and alleviation of disorder in phospholipid metabolism.